Jonatan Fernández-García

Jonatan Fernández-García

Auto-generated profile, based on publicly available information

Jonatan Fernández-García

Department of Medicine and General Cytometry Service-Nucleus, Proteomics Unit, CIBERONC CB16/12/00400, Cancer Research Center (IBMCC/CSIC/USAL/IBSAL), Universidad de Salamanca, Salamanca, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LZLiang Zheng
Liang Zheng
ZZZi-Ran Zhu
Zi-Ran Zhu
TSTal Sneh
Tal Sneh
WZWei-Tuo Zhang
Wei-Tuo Zhang
ZWZao-Yu Wang
Zao-Yu Wang
EGEyal Gottlieb
Eyal Gottlieb
Germline or somatic loss-of-function mutations of fumarate hydratase (FH) predispose patients to an aggressive form of renal cell carcinoma (RCC). Since other than tumor resection there is no effective therapy for metastatic FH-deficient RCC, an accurate method for early diagnosis is needed. Although MRI or CT scans are offered, they cannot differentiate FH-deficient tumors from other RCCs. Therefore, finding noninvasive plasma biomarkers suitable for rapid diagnosis, screening, and surveillance would improve clinical outcomes. Taking advantage of the robust metabolic rewiring that occurs in FH-deficient cells, we performed plasma metabolomics analysis and identified 2 tumor-derived metabolites, succinyl-adenosine and succinic-cysteine, as excellent plasma biomarkers for early diagnosis. These 2 molecules reliably reflected the FH mutation status and tumor mass. We further identified the enzymatic cooperativity by which these biomarkers are produced within the tumor microenvironment. Longitudinal monitoring of patients demonstrated that these circulating biomarkers can be used for reporting on treatment efficacy and identifying recurrent or metastatic tumors.

12 January 2024 in Science Immunology
Verified
Journal Article
Closed access
JSJulian Staniek
Julian Staniek
TKTomas Kalina
Tomas Kalina
GAGeoffroy Andrieux
Geoffroy Andrieux
MBMelanie Boerries
Melanie Boerries
IJIga Janowska
Iga Janowska
MRMarta Rizzi
Marta Rizzi
Defective FAS (CD95/Apo-1/TNFRSF6) signaling causes autoimmune lymphoproliferative syndrome (ALPS). Hypergammaglobulinemia is a common feature in ALPS with FAS mutations (ALPS-FAS), but paradoxically, fewer conventional memory cells differentiate from FAS-expressing germinal center (GC) B cells. Resistance to FAS-induced apoptosis does not explain this phenotype. We tested the hypothesis that defective non-apoptotic FAS signaling may contribute to impaired B cell differentiation in ALPS. We analyzed secondary lymphoid organs of patients with ALPS-FAS and found low numbers of memory B cells, fewer GC B cells, and an expanded extrafollicular (EF) B cell response. Enhanced mTOR activity has been shown to favor EF versus GC fate decision, and we found enhanced PI3K/mTOR and BCR signaling in ALPS-FAS splenic B cells. Modeling initial T-dependent B cell activation with CD40L in vitro, we showed that FAS competent cells with transient FAS ligation showed specifically decreased mTOR axis activation without apoptosis. Mechanistically, transient FAS engagement with involvement of caspase-8 induced nuclear exclusion of PTEN, leading to mTOR inhibition. In addition, FASL-dependent PTEN nuclear exclusion and mTOR modulation were defective in patients with ALPS-FAS. In the early phase of activation, FAS stimulation promoted expression of genes related to GC initiation at the expense of processes related to the EF response. Hence, our data suggest that non-apoptotic FAS signaling acts as molecular switch between EF versus GC fate decisions via regulation of the mTOR axis and transcription. The defect of this modulatory circuit may explain the observed hypergammaglobulinemia and low memory B cell numbers in ALPS.

Verified
Journal Article
Open access
PDF file
LWLubna Willi
Lubna Willi
IAIfat Abramovich
Ifat Abramovich
JFJonatan Fernandez-Garcia
Jonatan Fernandez-Garcia
BABella Agranovich
Bella Agranovich
MSMargarita Shulman
Margarita Shulman
EGEyal Gottlieb
Eyal Gottlieb
Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene and dilated cardiomyopathy (DCM) is a major cause of morbidity and mortality in DMD patients. We tested the hypothesis that DCM is caused by metabolic impairments by employing induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) generated from four DMD patients; an adult male, an adult female, a 7-year-old (7y) male and a 13-year-old (13y) male, all compared to two healthy volunteers. To test the hypothesis, we measured the bioenergetics, metabolomics, electrophysiology, mitochondrial morphology and mitochondrial activity of CMs, using respirometry, LC–MS, patch clamp, electron microscopy (EM) and confocal microscopy methods. We found that: (1) adult DMD CMs exhibited impaired energy metabolism and abnormal mitochondrial structure and function. (2) The 7y CMs demonstrated arrhythmia-free spontaneous firing along with “healthy-like” metabolic status, normal mitochondrial morphology and activity. In contrast, the 13y CMs were mildly arrhythmogenic and showed adult DMD-like bioenergetics deficiencies. (3) In DMD adult CMs, mitochondrial activities were attenuated by 45–48%, whereas the 7y CM activity was similar to that of healthy CMs. (4) In DMD CMs, but not in 7y CMs, there was a 75% decrease in the mitochondrial ATP production rate compared to healthy iPSC-CMs. In summary, DMD iPSC-CMs exhibit bioenergetic and metabolic impairments that are associated with rhythm disturbances corresponding to the patient’s phenotype, thereby constituting novel targets for alleviating cardiomyopathy in DMD patients.

2 October 2018
Verified
Book Chapter
Closed access
PDF file
RGRodrigo García-Valiente
Rodrigo García-Valiente
JFJonatan Fernández-García
Jonatan Fernández-García
JCJavier Carabias-Sánchez
Javier Carabias-Sánchez
AVAlicia Landeira Viñuela
Alicia Landeira Viñuela
RGRafael Gongora
Rafael Gongora
MFManuel Fuentes
Manuel Fuentes

26 September 2018
Verified
Book Chapter
Open access
PDF file
PJPablo Juanes-Velasco
Pablo Juanes-Velasco
JCJavier Carabias-Sanchez
Javier Carabias-Sanchez
RGRodrigo Garcia-Valiente
Rodrigo Garcia-Valiente
JFJonatan Fernandez-García
Jonatan Fernandez-García
RGRafael Gongora
Rafael Gongora
Manuel FuentesManuel Fuentes
Manuel Fuentes
Despite the tremendous advances in the understanding of the molecular mechanisms and the complexity of the diseases is one of the present challenges for the scientific community; then, novel strategies are required to be designed and developed for effective strategies for early diagnosis and treatment. As many cellular alterations are observed at protein level, high-throughput assays are dramatically needed for biomarker discovery. Herein, we describe advantages and limitations of protein microarrays, as proteomics strategy useful for multiplex and high-throughput protein characterization in clinical samples. Finally, a few examples are discussed; mostly of them related to currently disease biomarkers already identified in proximal fluids by protein arrays are discussed.

1 July 2019 in JAMIA Open
Verified
Journal Article
Open access
PDF file
ASAdam Spiro
Adam Spiro
JGJonatan Fernández García
Jonatan Fernández García
CYChen Yanover
Chen Yanover
Objectives: Identifying new relations between medical entities, such as drugs, diseases, and side effects, is typically a resource-intensive task, involving experimentation and clinical trials. The increased availability of related data and curated knowledge enables a computational approach to this task, notably by training models to predict likely relations. Such models rely on meaningful representations of the medical entities being studied. We propose a generic features vector representation that leverages co-occurrences of medical terms, linked with PubMed citations. Materials and Methods: We demonstrate the usefulness of the proposed representation by inferring two types of relations: a drug causes a side effect and a drug treats an indication. To predict these relations and assess their effectiveness, we applied 2 modeling approaches: multi-task modeling using neural networks and single-task modeling based on gradient boosting machines and logistic regression. Results: These trained models, which predict either side effects or indications, obtained significantly better results than baseline models that use a single direct co-occurrence feature. The results demonstrate the advantage of a comprehensive representation. Discussion: Selecting the appropriate representation has an immense impact on the predictive performance of machine learning models. Our proposed representation is powerful, as it spans multiple medical domains and can be used to predict a wide range of relation types. Conclusion: The discovery of new relations between various medical entities can be translated into meaningful insights, for example, related to drug development or disease understanding. Our representation of medical entities can be used to train models that predict such relations, thus accelerating healthcare-related discoveries.